Hakim Djaballah PhD

Dr. Hakim Djaballah is currently the Founder, President & CEO of Keren Therapeutics. The mission of IP-K is to improve the speed and reliability of drug discovery through Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experience in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr. Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.